Dias-Solange D, Le M, Gottipati K, Choi K
Sci Adv. 2025; 11(11):eads6862.
PMID: 40073119
PMC: 11900867.
DOI: 10.1126/sciadv.ads6862.
Yao C, Ye G, Yang Q, Chen Z, Yang M
Curr Protein Pept Sci. 2024; 25(6):438-442.
PMID: 38934364
DOI: 10.2174/0113892037280719231214095428.
Amblard F, LeCher J, De R, Zhou S, Liu P, Goh S
Eur J Med Chem. 2024; 268:116263.
PMID: 38432056
PMC: 11188152.
DOI: 10.1016/j.ejmech.2024.116263.
Ghosh A, Yadav M, Iddum S, Ghazi S, Lendy E, Jayashankar U
Eur J Med Chem. 2024; 267:116132.
PMID: 38335815
PMC: 10964431.
DOI: 10.1016/j.ejmech.2024.116132.
Stubbing L, Hubert J, Bell-Tyrer J, Hermant Y, Yang S, McSweeney A
RSC Chem Biol. 2023; 4(8):533-547.
PMID: 37547456
PMC: 10398354.
DOI: 10.1039/d3cb00075c.
Advances in anti-EV-A71 drug development research.
Wang S, Pang Z, Fan H, Tong Y
J Adv Res. 2023; 56:137-156.
PMID: 37001813
PMC: 10834817.
DOI: 10.1016/j.jare.2023.03.007.
Computational and experimental studies of salvianolic acid A targets 3C protease to inhibit enterovirus 71 infection.
Shi S, Xie L, Ma S, Xu B, An H, Ye S
Front Pharmacol. 2023; 14:1118584.
PMID: 36937869
PMC: 10017496.
DOI: 10.3389/fphar.2023.1118584.
Structural similarities between SARS-CoV2 3CL and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals.
Bafna K, Cioffi C, Krug R, Montelione G
Front Chem. 2022; 10:948553.
PMID: 36353143
PMC: 9638714.
DOI: 10.3389/fchem.2022.948553.
Total synthesis of antiviral drug, nirmatrelvir (PF-07321332).
Shekhar C, Nasam R, Paipuri S, Kumar P, Nayani K, Pabbaraja S
Tetrahedron Chem. 2022; 4:100033.
PMID: 36276807
PMC: 9579207.
DOI: 10.1016/j.tchem.2022.100033.
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations.
Joyce R, Hu V, Wang J
Med Chem Res. 2022; 31(10):1637-1646.
PMID: 36060104
PMC: 9425786.
DOI: 10.1007/s00044-022-02951-6.
A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.
Vankadara S, Dawson M, Fong J, Oh Q, Ang Q, Liu B
ACS Med Chem Lett. 2022; 13(8):1345-1350.
PMID: 35971455
PMC: 9331150.
DOI: 10.1021/acsmedchemlett.2c00260.
Enterovirus A71 antivirals: Past, present, and future.
Wang J, Hu Y, Zheng M
Acta Pharm Sin B. 2022; 12(4):1542-1566.
PMID: 35847514
PMC: 9279511.
DOI: 10.1016/j.apsb.2021.08.017.
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
Wang H, Pei R, Li X, Deng W, Xing S, Zhang Y
Eur J Med Chem. 2022; 238:114458.
PMID: 35635946
PMC: 9098890.
DOI: 10.1016/j.ejmech.2022.114458.
Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.
Brogi S, Ibba R, Rossi S, Butini S, Calderone V, Gemma S
Molecules. 2022; 27(8).
PMID: 35458759
PMC: 9029279.
DOI: 10.3390/molecules27082561.
4-Iminooxazolidin-2-One as a Bioisostere of Cyanohydrin Suppresses EV71 Proliferation by Targeting 3C.
Xu B, Liu M, Ma S, Ma Y, Liu S, Shang L
Microbiol Spectr. 2021; 9(3):e0102521.
PMID: 34787443
PMC: 8597634.
DOI: 10.1128/Spectrum.01025-21.
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
Bai B, Arutyunova E, Khan M, Lu J, Joyce M, Saffran H
RSC Med Chem. 2021; 12(10):1722-1730.
PMID: 34778773
PMC: 8529539.
DOI: 10.1039/d1md00247c.
Janus All-Cis 2,3,4,5,6-Pentafluorocyclohexyl Building Blocks Applied to Medicinal Chemistry and Bioactives Discovery Chemistry.
Clark J, Neyyappadath R, Yu C, Slawin A, Cordes D, OHagan D
Chemistry. 2021; 27(64):16000-16005.
PMID: 34486192
PMC: 9292521.
DOI: 10.1002/chem.202102819.
Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19.
Bhati S, Kaushik V, Singh J
J Mol Struct. 2021; 1237:130380.
PMID: 33840835
PMC: 8024110.
DOI: 10.1016/j.molstruc.2021.130380.
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Iketani S, Forouhar F, Liu H, Hong S, Lin F, Nair M
Nat Commun. 2021; 12(1):2016.
PMID: 33795671
PMC: 8016852.
DOI: 10.1038/s41467-021-22362-2.
Recent advances of enterovirus 71 targeting Inhibitors.
Diarimalala R, Hu M, Wei Y, Hu K
Virol J. 2020; 17(1):173.
PMID: 33176821
PMC: 7657364.
DOI: 10.1186/s12985-020-01430-x.